Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5337669 | 0.89 | KDM4E (0.38) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL5340287 | 0.87 | KDM4E (0.40) | ADAMTS4KDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL5352932 | 0.84 | MAPK1 (0.34) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL5344796 | 0.84 | BCL2 (0.34) | KDM4EALDH1A1SMN1; SMN2LMNAHPGD | |
| SCHEMBL5340966 | 0.83 | CYP2D6 (0.35) | KDM4EALDH1A1SMN1; SMN2LMNAESR1 | |
| SCHEMBL5338872 | 0.81 | KDM4E (0.36) | KDM4ELMNAESR1CHRM1SLC6A4 | |
| SCHEMBL5353271 | 0.80 | LMNA (0.34) | KDM4EALDH1A1SMN1; SMN2LMNAESR1 | |
| SCHEMBL5353123 | 0.79 | KDM4E (0.35) | ADAMTS4KDM4ELMNAESR1CHRM1 | |
| SCHEMBL5346495 | 0.79 | MTOR (0.38) | KCNH2 | |
| SCHEMBL5346815 | 0.78 | MAPK1 (0.41) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205291-B2 | High mouth absorption; antibiotics against gramnegative, grampositive bacteria espscially Staphlococcus pneumonia, Hemophilus influenza | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| US-20050020566-A1 | Novel carbapenem compounds | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1443047-A1 | NOVEL CARBAPENEM COMPOUNDS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020566-A1 | Novel carbapenem compounds | HPN, PRSS1, BPGM | ADAMTS4 2053/4885KDM4E 3734/4885NPC1 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.